We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry and Prevalence of Gene Mutation in Korean Patients With Familial Hypertrophic Cardiomyopathy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01792960
First Posted: February 15, 2013
Last Update Posted: February 19, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Yonsei University
February 7, 2013
February 15, 2013
February 19, 2014
February 2013
August 2013   (Final data collection date for primary outcome measure)
1) DNA analysis [ Time Frame: 1 year ]
1) Identify susceptible genes for familial hypertrophic cardiomyopathy in Korean
Same as current
Complete list of historical versions of study NCT01792960 on ClinicalTrials.gov Archive Site
2) Prognosis of familial hypertrophic cariomyopathy [ Time Frame: 1 year ]
2) all-cause mortality, hospitalization for heart failure progression, stroke, heart transplantation
Same as current
Not Provided
Not Provided
 
Registry and Prevalence of Gene Mutation in Korean Patients With Familial Hypertrophic Cardiomyopathy
Not Provided
Set the Korean Familial Hypertrophic Cardiomyopathy (KFHC) registry to study the prevalence of gene mutations in Korean patients with familial hypertrophic cardiomyopathy
Not Provided
Observational [Patient Registry]
Observational Model: Cohort
Time Perspective: Prospective
2 Years
Retention:   Samples With DNA
Description:
serum, whole blood, DNA
Non-Probability Sample
familial hypertrophic cardiomyopathy patients and their relatives
Familial Hypertrophic Cardiomyopathy
Not Provided
familial hypertrophic cardiomyopathy
familial hypertrophic cardiomyopathy patients and their relatives
Not Provided
 
Completed
99
August 2013
August 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. left ventricular maximal wall thickness ≥ 15mm on echocardiography
  2. hypertrophic cardiomyopathy patients' relatives

Exclusion Criteria:

  1. other cardiomyopathy or systemic disease (e.g. fabry disease, danon disease, glycogen storage disease)
  2. who deny the study entrance, especially in patients' relatives
Sexes Eligible for Study: All
13 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01792960
4-2012-0869
Yes
Not Provided
Not Provided
Yonsei University
Yonsei University
Not Provided
Not Provided
Yonsei University
February 2014